Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine renal dysfunction.

S Vítko1, O Viklický

  • 1Transplant Center, Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. stefan.vitko@medicon.cz

Transplantation Proceedings
|March 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients.

Physiological research·2024
Same author

Insights into IL-1 family cytokines in kidney allograft transplantation: IL-18BP and free IL-18 as emerging biomarkers.

Cytokine·2024
Same author

Antibody-mediated rejection of renal allografts: diagnostic pitfalls and challenges.

Physiological research·2022
Same author

SARS-CoV-2 viral load assessment in lung transplantation.

Physiological research·2021
Same author

Changes in phenotypic patterns of blood monocytes after kidney transplantation and during acute rejection.

Physiological research·2021
Same author

The relationship between lower urinary tract dysfunctions and urinary leakage from ureterocystoneoanastomosis in male patients after kidney transplantation.

Bratislavske lekarske listy·2021

Cyclosporine (CsA) is a vital immunosuppressant for organ transplants but causes kidney dysfunction. New strategies aim to reduce CsA toxicity while maintaining transplant success and minimizing rejection.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Cyclosporine (CsA) is a cornerstone immunosuppressant in organ transplantation, introduced in the 1980s.
  • Despite its efficacy, CsA is associated with significant renal dysfunction, complicating long-term graft survival.
  • Histopathological changes induced by CsA can mimic chronic allograft nephropathy, posing diagnostic challenges.

Purpose of the Study:

  • To review current strategies for minimizing CsA-induced nephrotoxicity in organ transplant recipients.
  • To explore novel approaches in immunosuppressive therapy to reduce reliance on CsA.
  • To highlight the role of therapeutic drug monitoring and pharmacogenetics in managing CsA therapy.

Main Methods:

  • Review of recent clinical experience and emerging protocols for CsA-sparing strategies.

Related Experiment Videos

  • Analysis of four distinct CsA-sparing approaches: conversion, minimal exposure, withdrawal, and CsA-free protocols.
  • Discussion of advanced monitoring techniques including C2 blood levels and pharmacogenetics.

    • Main Results:

    • Four CsA-sparing strategies have been developed to mitigate nephrotoxicity while preserving immunosuppression.
    • C2 blood level monitoring may reduce CsA toxicity, but optimal targets require further definition.
    • Pharmacogenetic information can personalize immunosuppressive regimens, potentially lowering toxicity.

    Conclusions:

    • Cyclosporine (CsA) remains a critical immunosuppressant, but its nephrotoxicity is a persistent clinical challenge.
    • Emerging CsA-sparing protocols and advanced monitoring offer promising avenues to improve patient outcomes.
    • Personalized immunosuppression using pharmacogenetics holds potential for safer, more effective transplant management.